BridgeBio Pharma Inc.

30.94+2.23+7.77%Vol 1.42M1Y Perf 211.05%
Dec 1st, 2023 16:00 DELAYED
BID30.74 ASK31.00
Open28.50 Previous Close28.71
Pre-Market- After-Market30.75
 - -  -0.19 -0.61%
Target Price
20.38 
Analyst Rating
Strong Buy 1.30
Potential %
-34.13 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/100/50 
Value Ranking
★★     45.82
Insiders Value % 3/6/12 mo.
-/100/-16 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/100/36 
Income Ranking
 —    -
Price Range Ratio 52W %
81.76 
Earnings Rating
Market Cap5.38B 
Earnings Date
2nd Nov 2023
Alpha0.02 Standard Deviation0.25
Beta1.00 

Today's Price Range

27.7430.98

52W Range

6.6436.36

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
4.60%
1 Month
14.93%
3 Months
1.18%
6 Months
116.97%
1 Year
211.05%
3 Years
-36.66%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BBIO30.942.23007.77
AAPL191.241.29000.68
GOOG133.32-0.6000-0.45
MSFT374.51-4.4000-1.16
XOM102.990.25000.24
WFC45.020.43000.96
JNJ158.383.72002.41
FB196.640.99000.51
GE122.500.70000.57
JPM156.840.76000.49
Financial StrengthValueIndustryS&P 500US Markets
5.20
5.40
0.89
8.56
-5.60
Leverage Ratio -0.70
ProfitabilityValueIndustryS&P 500US Markets
95.10
-474.60
-467.10
-
-
RevenueValueIndustryS&P 500US Markets
75.78M
0.51
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.86-1.08-25.58
Q02 2023-0.86-0.98-13.95
Q01 2023-0.84-0.92-9.52
Q04 2022-0.86-0.87-1.16
Q03 2022-1.02-0.938.82
Q02 2022-0.92-0.8111.96
Q01 2022-1.13-1.19-5.31
Q04 2021-0.83-1.01-21.69
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.86
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume1.42M
Shares Outstanding173.97K
Shares Float95.49M
Trades Count17.99K
Dollar Volume42.75M
Avg. Volume1.22M
Avg. Weekly Volume1.12M
Avg. Monthly Volume1.19M
Avg. Quarterly Volume1.37M

BridgeBio Pharma Inc. (NASDAQ: BBIO) stock closed at 30.94 per share at the end of the most recent trading day (a 7.77% change compared to the prior day closing price) with a volume of 1.42M shares and market capitalization of 5.38B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 396 people. BridgeBio Pharma Inc. CEO is Neil Kumar.

The one-year performance of BridgeBio Pharma Inc. stock is 211.05%, while year-to-date (YTD) performance is 306.04%. BBIO stock has a five-year performance of %. Its 52-week range is between 6.64 and 36.36, which gives BBIO stock a 52-week price range ratio of 81.76%

BridgeBio Pharma Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 123.68, a price-to-sale (PS) ratio of 14.70, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -70.57%, a ROC of -63.99% and a ROE of 55.51%. The company’s profit margin is -%, its EBITDA margin is -467.10%, and its revenue ttm is $75.78 Million , which makes it $0.51 revenue per share.

Of the last four earnings reports from BridgeBio Pharma Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.86 for the next earnings report. BridgeBio Pharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BridgeBio Pharma Inc. is Strong Buy (1.3), with a target price of $20.38, which is -34.13% compared to the current price. The earnings rating for BridgeBio Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BridgeBio Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BridgeBio Pharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.37, ATR14 : 1.55, CCI20 : 110.89, Chaikin Money Flow : 0.12, MACD : 0.76, Money Flow Index : 56.20, ROC : 12.43, RSI : 63.08, STOCH (14,3) : 99.17, STOCH RSI : 1.00, UO : 60.63, Williams %R : -0.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BridgeBio Pharma Inc. in the last 12-months were: Brian C. Stephenson (Option Excercise at a value of $0), Brian C. Stephenson (Sold 157 514 shares of value $1 793 976 ), Charles J. Homcy (Option Excercise at a value of $0), Homcy Charles (Sold 0 shares of value $0 ), Kumar Neil (Sold 0 shares of value $0 ), Kumar Neil (Sold 51 552 shares of value $1 500 253 ), Neil Kumar (Option Excercise at a value of $0), Neil Kumar (Sold 364 798 shares of value $1 889 770 ), Randal W. Scott (Sold 2 500 shares of value $75 000 ), Richard H. Scheller (Option Excercise at a value of $0), Stephenson Brian (Sold 0 shares of value $0 ), Stephenson Brian (Sold 392 710 shares of value $5 481 322 ), Valantine Hannah (Sold 0 shares of value $-24 632 ), Valantine Hannah (Sold 2 915 shares of value $87 450 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (80.00 %)
7 (77.78 %)
8 (80.00 %)
Moderate Buy
1 (10.00 %)
1 (11.11 %)
1 (10.00 %)
Hold
1 (10.00 %)
1 (11.11 %)
1 (10.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.30
Strong Buy
1.33
Strong Buy
1.30

BridgeBio Pharma Inc.

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

CEO: Neil Kumar

Telephone: +1 650 391-9740

Address: 421 Kipling Street, Palo Alto 94301, CA, US

Number of employees: 396

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

45%55%

Bearish Bullish

51%49%

Bearish Bullish

58%42%

 

TipRanks News for BBIO

Mon, 13 Nov 2023 02:10 GMT Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Biogen (BIIB) and Becton Dickinson (BDX)

- TipRanks. All rights reserved.

Sun, 12 Nov 2023 23:50 GMT Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BridgeBio Pharma (BBIO) and Boston Scientific (BSX)

- TipRanks. All rights reserved.

Tue, 07 Nov 2023 09:37 GMT Promising Future for BridgeBio Pharma: Lebovitzs Buy Rating Backed by Potential Blockbusters and Pipeline Assets

- TipRanks. All rights reserved.

Thu, 02 Nov 2023 22:00 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: American Well (AMWL), BridgeBio Pharma (BBIO) and Idexx Laboratories (IDXX)

- TipRanks. All rights reserved.

Wed, 11 Oct 2023 06:30 GMT Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Syndax Pharmaceuticals (SNDX)

- TipRanks. All rights reserved.

Thu, 07 Sep 2023 11:10 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (BBIO) and BioMarin Pharmaceutical (BMRN)

- TipRanks. All rights reserved.

Tue, 29 Aug 2023 12:31 GMT Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Alkermes (ALKS)

- TipRanks. All rights reserved.

Mon, 28 Aug 2023 13:20 GMT Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), GE Healthcare Technologies Inc (GEHC) and Sotera Health (SHC)

- TipRanks. All rights reserved.

Mon, 28 Aug 2023 02:30 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Paycor HCM (PYCR), BridgeBio Pharma (BBIO) and Evolent Health (EVH)

- TipRanks. All rights reserved.

Mon, 17 Jul 2023 13:25 GMT BridgeBio Pharma (BBIO) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

Wed, 05 Jul 2023 16:35 GMT BridgeBio Pharma (BBIO) Gets a Buy from Mizuho Securities

- TipRanks. All rights reserved.

News

Stocktwits